Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: May 13, 2024
Reporting Period: First Quarter ended March 31, 2024
Business Overview: The filing announces the release of financial results for the quarter ended March 31, 2024, and provides a corporate update.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the detailed financial data but does not include the specific numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not contain specific comparative data or material changes versus the prior period. It only indicates that such results were announced in a press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the Company issued a press release titled "Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update."
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release) for specific revenue, net loss, and cash position figures for Q1 2024.
- Verify the "Corporate Update" section in the press release for details on clinical trial progress or strategic initiatives.
- Check the Company's subsequent 10-Q filing for the audited or reviewed financial statements corresponding to this period.
- Confirm the trading status of Common Stock (Symbol: CAPR) on The Nasdaq Capital Market.